News
GLUE ▲ +15.0% - Monte Rosa Therapeutics, Inc.
GLUE ▲ +15.0% - Monte Rosa Therapeutics, Inc.
$GLUE - Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
01-OCT-2026 07:00 AM ET
Share this post
More filings for $GLUE
GLUE ▲ +5.8% - Monte Rosa Therapeutics, Inc.Sep 30, 2026GLUE ▲ +1.2% - Monte Rosa Therapeutics, Inc.Sep 8, 2026GLUE ▼ -0.5% - Monte Rosa Therapeutics, Inc.Sep 2, 2026GLUE ▼ -0.2% - Monte Rosa Therapeutics, Inc.Sep 1, 2026$GLUE SEC Filing Update (08-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 8, 2026$GLUE SEC Filing Update (06-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 6, 2026
View full $GLUE filing history →💬 Comments
Loading comments…
Leave a comment